Related Experiment Video
Updated: Jun 4, 2025
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.1K
Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?
Pranesh Ravichandran1, Cecilia Canizela1, Abrahem Sayed2
1College of Medicine, University of Illinois, Peoria, IL.
International Ophthalmology Clinics
|December 23, 2024
Summary
Novel tyrosine kinase inhibitors (TKIs) offer a promising alternative to frequent anti-VEGF injections for retinal diseases. These new TKIs may reduce treatment burden and improve outcomes for conditions like AMD and DME.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Dysregulated vascular endothelial growth factor receptor tyrosine kinases drive retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME).
- These conditions are leading causes of vision loss with increasing global prevalence.
- Current treatments involve frequent anti-vascular endothelial growth factor (anti-VEGF) injections, posing a significant patient burden.
Purpose of the Study:
- To review novel tyrosine kinase inhibitors (TKIs) currently in development for exudative retinal diseases.
- To explore how different TKI technologies and molecular targets may improve patient outcomes.
- To highlight the potential of TKIs to reduce treatment frequency compared to standard care.
Main Methods:
- Literature review of preclinical and clinical studies on TKIs for retinal diseases.
- Analysis of TKI mechanisms targeting angiogenesis and exudation pathways.
- Comparison of TKI therapeutic potential against current anti-VEGF therapies.
Main Results:
- TKIs inhibit key signaling pathways involved in pathological angiogenesis and vascular leakage.
- Emerging TKIs demonstrate potential for broader molecular targeting than current anti-VEGF agents.
- Developmental TKIs aim to offer improved efficacy and reduced administration frequency.
Conclusions:
- Novel TKIs represent a significant advancement in managing exudative retinal diseases.
- Targeting multiple pathways with TKIs may lead to enhanced visual and anatomic outcomes.
- TKIs hold promise for reducing the treatment burden associated with chronic retinal conditions.
More Related Videos
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.0K
06:48Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
21.1K
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Open Angle Glaucoma: Treatment
391
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475